• Just like a chameleon utilizing its
    colored pigments and crystals to
    adapt to its surroundings,
    we proactively pioneer and adapt to
    the everchanging NGS markets with
    our cutting-edge technology to
    support our customer’s needs.

Celemics Promotions

Discover our recent promotion information

Celemics continues to provide various support and benefits for our client's business success
Our promotions aim to assist in successful research & business
by providing easy customer access to the latest Celemics
NGS-based products and services

Discover Celemics' current Promotions and
experience its special benefits!

BTSeq™ Promotion
Analyze DNA samples without primer design and primer
walking at less than Sanger sequencing costs!
CES Promotion
Explore an exciting opportunity for a low-cost entry into
NGS-based Clinical Exome Sequencing

BTSeq™ 2 years Anniversary Free Trial Promotion

Free for your first order!

Introducing BTSeq™, Our NGS-based Sequencing Solution

Claim your free trial now!
Still Using Sanger Sequencing?
Tired of Primer Design?
Celemics' BTseq service sequences DNA samples from 200 bp to 20 kb without
the need for primer design or primer walking at less than the cost of Sanger sequencing.
Inquires on BTSeq™ Free Trial (Promotional Benefits for First 100 Customers)

Clinical Exome Sequencing (CES) Promotion

G-Mendeliome Clinical Exome Sequencing Panel

Focus on Clinical Exome Sequencing!
Promotional Price : 69 USD
[Including Target Enrichment kit and BI analysis]
Contact Us
Utilizing one broad exome panel has raised many issues of poor coverage
Most whole exome sequencing panels often cover less of the whole exome than required, with data indicating
that 50 percent of exons have lower than 30x average coverage. Due to the low-coverage regions,
WES can miss critically important variant regions.
Variant calling and clinical interpretation still requires extensive expertise and time
Clinical exome sequencing data analysis still demands both technical expertise and significant time expenditure.
Clinical interpretation of various detected variants is very challenging as it involves a comprehensive
understanding of variants, drugs, guidelines, etc.

Streamline both targeted NGS panel and WES panel use and simplify your germline mutation profiling
test with G-Mendeliome Clinical Exome Sequencing panel, consistently yielding excellent
coverage over the desired target regions

Diagnose Rare Disease with CES/DES Panel
The G-Mendeliome Clinical Exome Sequencing Panel, CES (also known as the Diagnostics Exome Sequencing panel, DES, at GC Genome) was developed from the needs of GC Genome (https://www.gc-genome.com), the largest clinical NGS service provider in Korea.
CES solved the problem of poor diagnostics resulting from the large number of genes omitted from the inherited disease
panels of Companies A and B (Figure 1) and reduced costs by removing areas from both panels irrelevant to diagnosis.
GC Genome previously used the panels of both Company A and B, but have since replaced their workflow
using the G-Mendeliome CES Panel.

Comparison data : ZNF419 gene

이미지 Figure 1. Clinically significant regions of interest absent from competitor’s products
이미지 Figure 2. Customer Testimonial of GC Genome

Celemics Analysis Service (CAS) Workflow


Celemics' CES Panel is bundled with a free-of-charge CAS Secondary Report and powerful,
cost-effective Clinical Report, both optimized for your real-life clinical requirements.


01 Comprehensive genomics profiling of
a variety of genetic diseases
Includes 7,513 genes associated with clinically significant genetic diseases
02 A wide range of target regions Includes all clinically significant regions that are not covered by competing panels
03 Cost-effective analysis Able to provide accurate analysis
with lower sequencing cost compared to that of WES via CAS


01 Gene count 7,513 genes
02 Covered region CDS, intronic hotspots, mitochondrial genome
03 Target size 19.6 MB
04 Multiplexing 4-plex enrichment
05 Sample type 50 ng of gDNA
06 Platform All sequencers of illumina
07 Bioinformatics pipeline Primary, secondary, and tertiary analysis via CAS (Fastq to annotated VCF)
Clinical Report via Strand (VCF to clinical report)



Incidental Severe Fatty Degeneration of the Erector Spinae in a Patient with L5–S1
Disc Extrusion Diagnosed with Limb-Girdle Muscular Dystrophy R2 Dysferin-Related

Kim et al, Diagnostics 2020, 10, 530; doi:10.3390/diagnostics10080530